Alopecia Areata – HZNP-DAX-201

A Phase 2A, Open Label, Proof-of-Concept Trial of Daxdilimab for the Treatment of Moderate-to-Severe Alopecia Areata


Register Today!

Trial Information

Start DateNovember 2022
End DateTBD
Trial Duration ~ 1 year
Number of Visits15
Lead CRCMarija Bernstein
StatusIn Start-Up

For additional information
on this trial contact:

Phone705-566-0005